Oragenics (OGEN) provided an update on its strategic progress since its last capital raise in September 2024. The Company also announced the appointment of Janet Huffman as its new interim Chief Executive Officer. Following the Company’s $4 million capital raise in September 2024, the Company has made significant advancements, including: Formulation and Device Enhancements; Advancing Phase II Preparations; Supply Chain Preparedness; Prototyping for Enhanced Accessibility; Regulatory Milestones
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGEN: